Hello,
Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:
- We got the scoop that Amazon's gearing up to launch its telehealth business nationally;
- How Sage Therapeutics is trying to avoid another flop with its second drug;
- ElevateBio raises $525 million from investors including SoftBank.
If you're new to this newsletter, sign up here. Comments, tips, recipes? Email me at [email protected] or tweet @lydiaramsey125. Now, let's get to it…

The Amazon Care app.
Amazon Care

Amazon Care
Amazon is gearing up to launch its telehealth business for other companies and the rest of its US employees
- Amazon is expanding its healthcare business, Amazon Care, nationally.
- It started the service, which does telehealth and home visits, with Amazon workers in Washington.
- Amazon Care is the beginning of Amazon's efforts to change how people in the US get healthcare.

Businesswire
Sage's first depression drug flopped. The biotech's CEO shares how he's trying to avoid a repeat with its next treatment.
- Barry Greene took over as Sage's CEO after it cut the entire sales force behind its first drug.
- Its second drug, zuranolone, must compete with cheap depression drugs already on the market.
- The zuranolone launch could also affect Biogen's business, thanks to a $3.1 billion partnership.
Check out more from the conversation here>>

ElevateBio's front desk is seen in Cambridge, Massachusetts.
ElevateBio

ElevateBio
SoftBank is betting on a gene therapy biotech in a mammoth $525 million round. ElevateBio's CEO told us how he plans to use the cash to support a genetic revolution in medicine.
- The Massachusetts biotech ElevateBio raised $525 million in an industry-record Series C round.
- The company produces cell- and gene-therapy medicines and is also now making its own research bets.
- The latest raise includes funds from the investment firm SoftBank.
More stories we're reading today:
- Former Theranos CEO Elizabeth Holmes is pregnant, and is requesting her federal trial be delayed again (Insider)
- Having 3 authorized vaccines makes testing new ones more complicated (Wired)
- One chart shows how well COVID-19 vaccines work against the 3 most worrisome coronavirus variants (Insider)
- People who are immunocompromised and get COVID-19 might play a role in the mutating variants (Washington Post)
- Is it a crime to give away leftover COVID shots? Doctors and other healthcare workers fear legal consequences as they wait for Justice Department guidance. (Insider)
- Lydia
Read the original article on Business Insider